摘要
目的:对文拉法辛联合喹硫平治疗难治性抑郁症进行药物经济学评价。方法:74例难治性抑郁症患者随机分为试验组(n=38)与对照组(n=36),采用汉密顿抑郁量表(HAMD)分别在入组时与第12周末评估临床疗效,于12周末统计成本,并进行成本-效果分析。结果:试验组与对照组人均成本分别为1688.69元与1487.22元,HAMD评分减少量分别为14.5与10.2,成本-效果比分别为116.46与145.81。结论:2种治疗方案中,文拉法辛联合喹硫平是治疗难治性抑郁症较经济方案。
OBJECTIVE：To evaluate the pharmacoeconomics effectiveness of venlafaxine combined with quetiapine in the treatment of treatment-resistant depression.METHODS：74 patients with treatment-resistant depression were randomly divided into treatment group（n=38） and control group（n=36）.Clinical efficacies of 2 groups were evaluated at baseline and the end of 12 weeks treatment using Hamilton Rating Scale for Depression（HAMD）.The total cost of the two groups was calculated and cost-effectiveness analysis was carried out.RESULTS：The per capita cost of treatment group and control group were 1 688.69 and 1487.22 yuan.The HAMD reduction score of 2 groups were 14.5 and 10.2 and the C/E of 2 groups were 116.46 and 145.81,respectively.CONCLUSION：Venlafaxine combine with quetiapine is more economical and practical than venlafaxine alone in the treatment of treatment-resistant depression.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第20期1908-1909,共2页
China Pharmacy
关键词
难治性抑郁症
文拉法辛
喹硫平
成本-效果分析
Treatment-resistant depression
Venlafaxine
Quetiapine
Cost-effectiveness analysis
